[{"id":"1819cfb4-2350-4f2b-b20f-e71e12414bdf","acronym":"BOLD","url":"https://clinicaltrials.gov/study/NCT04015739","created_at":"2021-01-18T19:43:25.674Z","updated_at":"2024-07-02T16:36:05.333Z","phase":"Phase 2","brief_title":"Tri Association in Patient With Advanced Epithelial Ovarian Cancer in Relapse","source_id_and_acronym":"NCT04015739 - BOLD","lead_sponsor":"ARCAGY/ GINECO GROUP","biomarkers":" BRCA • MUC16","pipe":"","alterations":" ","tags":["BRCA • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Lynparza (olaparib) • Imfinzi (durvalumab) • Equidacent (bevacizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 03/01/2019","start_date":" 03/01/2019","primary_txt":" Primary completion: 06/30/2020","primary_completion_date":" 06/30/2020","study_txt":" Completion: 01/29/2024","study_completion_date":" 01/29/2024","last_update_posted":"2022-08-17"}]